Healthcare >> CEO Interviews >> August 27, 2013
Robin L. Smith has served as the Chairman and Chief Executive Officer of NeoStem, Inc., since 2006. While at NeoStem, Inc., Dr. Smith has successfully completed five acquisitions and one divestiture, as well as raised over $100 million toward building one of the leading companies in the emerging cell therapy industry. Dr. Smith has acted as a senior adviser to and investor in companies where she has played a significant role in restructuring and/or growth. She currently serves on the board of trustees of the NYU Langone Medical Center and is past Chairman of the board for the New York University Hospital for Joint Diseases, where she headed up new development efforts and board member recruitment. Currently, Dr. Smith is the President and Chairman of the board of the Stem for Life Foundation. She was also appointed to the board of directors, Science and Faith STOQ Foundation in Rome and the Capital Formation Committee of the Alliance for Regenerative Medicine. Dr. Smith received her M.D. from Yale University and was presented with the Janet M. Glasgow Memorial Achievement Citation awarded by the American Medical Women’s Association to women who graduate first in their class from medical school. She was also elected to Alpha Omega Alpha and chosen to be a Farr Scholar. She received her MBA from the Wharton School of Business in the top 10% of her class. Profile
TWST: Let's begin with a general background of NeoStem, how it got started and some of the more recent milestones or transitions over the past year or two.
Dr. Smith: